Evidence map›Paper›PMID 38858235›Full record

ArticleBreast cancer research and treatment2024

Second primary non-breast cancers in young breast cancer survivors.

Bessie X Zhang, Kristen D Brantley, Shoshana M Rosenberg, Gregory J Kirkner, Laura C Collins, Kathryn J Ruddy, Rulla M Tamimi, Lidia Schapira, Virginia F Borges, Ellen Warner and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bessie X Zhang *Harvard Medical School, Boston, MA, USA.
Kristen D Brantley *Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Shoshana M RosenbergWeill Cornell Medicine, New York, NY, USA.
Gregory J KirknerMedical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Laura C CollinsHarvard Medical School, Boston, MA, USA.
Kathryn J RuddyMayo Clinic, Rochester, MN, USA.
Rulla M TamimiWeill Cornell Medicine, New York, NY, USA.
Lidia SchapiraStanford University, Stanford, CA, USA.
Virginia F BorgesUniversity of Colorado Cancer Center, Denver, CO, USA.
Ellen WarnerSunnybrook Health Sciences Centre, Toronto, ON, Canada.
Steven E ComeHarvard Medical School, Boston, MA, USA.
Eric P WinerYale Cancer Center, New Haven, CT, USA.
Jennifer R BellonRadiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
Ann H PartridgeHarvard Medical School, Boston, MA, USA. ann_partridge@dfci.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated the incidence, timing, and risk factors for second primary non-breast cancers (SPNBC) among young breast cancer (BC) survivors.

methodsThis study included participants of the Young Women's BC Study (YWS) who were diagnosed with stage 0-III BC between 2006 and 2016 and age 40 or younger at diagnosis (N = 1,230). Patient characteristics, treatment information, and clinical events were collected via serial surveys. Tumor and treatment data were obtained from medical record review. Five- and 10-year risks of SPNBCs were estimated via the cumulative incidence function, considering death, metastasis, or second primary BC as competing events. Fine and Gray subdistribution hazard models estimated subdistribution hazard ratios (sHRs) and 95% confidence intervals (CI) for SPNBC risk based on risk factors including demographics, germline genetics, primary BC characteristics, and treatments.

resultsAmong 1,230 women, over a median follow-up of 10.1 years, 47 patients (4%) developed an SPNBC. Types of malignancy included melanoma (n = 10), thyroid (n = 10), ovarian (n = 4), sarcoma (n = 4), uterine (n = 3), rectal (n = 3), bladder (n = 2), cervical (n = 2), head/neck (n = 2), lung (n = 2), lymphoma (n = 2), pancreatic (n = 2), and renal (n = 1). Five and 10-year cumulative incidence were 1.4% and 3.2%, respectively. Median time between primary BC and SPNBC was 7.3 years. No patient factors, primary tumor characteristics, or treatments were statistically significantly associated with SPNBC in univariable or multivariable models.

conclusionIn this population, five-year cumulative incidence was higher than that reported among healthy women under 50 years of age, highlighting the importance of long-term surveillance for new non-breast cancers in young adult BC survivors.

Indexed as

Breast NeoplasmsCancer SurvivorsNeoplasms, Second PrimaryAdultFemaleFollow-Up StudiesHumansIncidenceRisk FactorsYoung AdultBreast cancer survivorsSecond primary cancer riskYoung women

Identifiers

PMID38858235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.